AGM PRESENTATION

7th November 2016

ASX: BD1

Transforming early cancer detection & prevention

For

per

sona

l use

onl

y

Forward StatementsThis presentation has been prepared by BARD1 Life Sciences Limited (“BARD1” or the “Company”) based on information available to it as at thedate of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary tomake an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security inBARD1, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financialsituation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment ofBARD1 and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of theinformation having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to theirjurisdiction and circumstances. BARD1 is not licensed to provide financial product advice in respect of its securities or any other financialproducts. Cooling off rights do not apply to the acquisition of BARD1 securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fairand reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of theinformation, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of BARD1 its officers,directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including,without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the informationcontained in this presentation or otherwise arising in connection with it.The information presented in this presentation is subject to change without notice and BARD1 does not have any responsibility or obligation toinform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in thispresentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

This presentation contains certain forward looking statements that are based on the Company’s management beliefs, assumptions andexpectations and on information currently available to management. Such forward looking statements involve known and unknown risks,uncertainties, and other factors which may cause the actual results or performance of BARD1 to be materially different from the results orperformance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptionsregarding the Company’s present and future business strategies and the political and economic environment in which BARD1 will operate in thefuture, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation orwarranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extentpermitted by law, BARD1 and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking torelease any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but notlimited to, any assumptions or expectations set out in the presentation).F

or p

erso

nal u

se o

nly

BARD1 Life Sciences (ASX:BD1)

■ Life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer

■ Leverages proprietary BARD1 technology that is a tumour suppressor in healthy individuals and important tumour biomarker in cancer

■ Focused on developing non-invasive diagnostic tests for early detection of cancer in US$100.9B cancer diagnostics market

■ Lead product BARD1 Lung Cancer Test is a simple blood test in development for early detection of lung cancer with potential convenience, accuracy & cost advantages

■ Completed POC Study validating BARD1 antibodies as biomarkers for detection of lung cancer and demonstrating high sensitivity and specificity of prototype BARD1 Test

■ Commenced Analytical Validation to further develop, optimise and validate BARD1 Test for early-stage lung cancer on proven ELISA platform

■ Planned Clinical Validation studies to prove the safety and performance of BARD1 Test as a screening test for early detection of lung cancer, expected to commence 2H17

■ Future pipeline of high-value diagnostics and therapeutics at research-stage for multiple cancers

■ Experienced leadership with track record in building successful companies, and international expertise in BARD1 biology, biomarker translation & respiratory medicine

For

per

sona

l use

onl

y

Company Snapshot

SUBSTANTIAL SHAREHOLDERS # SHARES % HOLDING

Irmgard Irminger 108,252,420 19.61%

Tony Walker 88,501,626 16.03%

Paul Sharbanee 33,911,561 6.14%

Peter Lynton Gunzburg 29,835,004 5.40%

1. Escrowed until Jul-18

Biotech focused on fast-to-market diagnostics with significant upside from potential high-value therapeutic pipeline for unmet needs in cancerKEY FINANCIALS

Ticker ASX:BD1

Ordinary Shares 551,996,586

Performance Shares1 217,003,236

Share Price (@4/11/16) A$0.036

Market Cap (@4/11/16) A$19.87m

52w Range A$0.041-0.019

Cash (@ 30/9/16) A$2.67m

For

per

sona

l use

onl

y

Leadership TeamExperience & expertise

Peter Gunzburg BCom | Executive Chairman

•Public company director, stockbroker and technology investor, with 20+ years corporate advisory, capital raising, transaction & business management experience

•Currently Chair of the Institute for Respiratory Health at UWA

•Previously director of Resolute Ltd, Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd, Fleetwood Corporation Ltd, Dragon Mining Ltd and Newzulu Ltd

Dr Irmgard Irminger-Finger PD PhD | Executive Director & Chief Scientific Officer

•Founder and co-inventor of BARD1 and its technology, and internationally recognised expert in BARD1 biology with over 40 publications, 6 issued patents, 30 collaborations and 150 conference presentations

•Currently Privat Docent at UNIGE, Head of the Molecular Gynaecology and Obstetrics Laboratory at HUG, and Adjoint Prof at UWA

•Former Executive Director & founder of BARD1Ag

Brett Montgomery | Non-Executive Director

•Extensive experience in public company management, leadership, corporate governance and risk management

•Currently Non-Executive Director of Tanami Gold NL, and Magnum Gas and Power Ltd

•Previously Managing Director of Kalimantan Gold NL, and Director of Grants Patch Mining Ltd and EZA Corporation Ltd

Prof Geoff Laurent PhD FRCP(Hon) FRCPath FMedSci | Non-Executive Director

•Accomplished organisational leader, thought-leader, scientific editor, advisory board member, and award winning respiratory scientist with over 300 peer reviewed publications

•Currently Director of the Institute for Respiratory Health, and Director of the Centre of Cell Therapy and Regenerative Medicine at UWA

•Former Vice-Dean of Enterprise & Head of Department of Internal Medicine at University College London, Past President of the British Association for Lung Research

Dr Leearne Hinch BSc BVMS MBA | Chief Executive Officer

•Biotechnology executive and consultant with extensive experience in the life science industry in general management, strategy, fundraising, business development and commercialisation

•Currently Director at Ingeneus Solutions

•Previously CEO of Eustralis Pharmaceuticals Ltd and Immuron Ltd, and executive at OBJ Ltd, Holista CollTech Ltd, Chemeq Ltd and Virbac (Australia) Pty Ltd

For

per

sona

l use

onl

y

Business ModelDevelop, validate, partner & profit

■ Focus on developing fast-to-market diagnostic tests for early detection of cancer that are reliable, accurate and affordable

■ Deliver clinical evidence to demonstrate medical value and enable medical device marketing or approval in Europe, Australia & USA

■ Commercialise through licensing of laboratory tests (LDTs) to central laboratories, or of approved in vitro diagnostics (IVDs) to multinational partners for royalties

■ Expand research to develop high-value therapeutic pipeline for unmet needs in cancer and partner early to biopharma partner for upfront fees, milestone payments & future royalties

■ Create value for ASX:BD1 shareholders

For

per

sona

l use

onl

y

BARD1 TechnologyScience■ BARD1 gene (BRCA1-associated RING domain 1) is a tumour suppressor coding for the BARD1 protein

□ BARD1 protein binds & stabilises the BRCA1 protein, otherwise unstable1

□ BRCA1 is responsible for DNA repair, whereas BRCA mutations increase the risk for breast cancer□ BARD1 is important in mitosis and required for cytokinesis, whereas BARD1 depletion leads to cell cycle arrest2

■ Cancer cells express a number of aberrant BARD1 isoforms generated by alternate gene splicing □ BARD1 isoforms antagonise the functions of ‘normal’ BARD1 and BRCA1 to drive oncogenesis3

□ Different combinations of BARD1 molecules are specific for different cancers4

□ BARD1 mutations identified in multiple non-coding & coding regions that predispose to cancer5

■ BARD1 isoforms have been correlated with cancer progression & poor prognosis6

■ BARD1 epitopes are novel and specific biomarkers for multiple cancers

Novel, proprietary & specific cancer biomarkers

1. Wu et al 1996; Irminger-Finger et al 20162. Ryser et al 2009; Zhang et al 2004; Delaval et al 2004; Daniels et al 2004 3. Ryser et al 2009; Bosse et al 20124. Wu et al 2006; Li et al 2007; Zhang et al 2012a; Zhang et al 2012b; Lepore et al 20135. Nowakowska et al 2015; Ratajska et al 20156. Zhang 2012a; Zhang 2012b; Wu et al 2006; Li 2007b

Normal BARD1

Antibodies

against regions

on normal

BARD1

For

per

sona

l use

onl

y

Cancer BARD1

Antibodies specific for cancer BARD1

Antibodies bind to small surface

regions of BARD1 (epitopes).

We use epitopes to capture

antibodies.

Peptides are 10-15 amino acids

long.

Biomarker Translation Scientific Rationale

■ BARD1 is potentially a diagnostic biomarker and therapeutic target for cancer□ Aberrant BARD1 proteins are released in large amounts by cancer cells and induce circulating BARD1

autoantibodies that can be detected early in the blood enabling early diagnosis of cancer1

□ BARD1 cancer-specific RNA-isoforms result in diagnostic signatures that can be detected by liquid biopsy methods1

□ Cancer-associated BARD1 isoforms can be targeted to inhibit their oncogenic potential enabling targeted therapies for prevention or treatment of cancer

■ Potential applications for Lung, Breast, Ovarian, Prostate, Colorectal & other cancers□ Global cancer diagnostics market valued at US $100.9B in 2013 & $168.6B by 20202

□ Global cancer therapeutics market was valued at US $78.2B in 2013 & $111.9B by 20203

1. Wu et al 2006; Li et al 2007; Zhang et al 2012a; Zhang et al 2012b2. TMR. Cancer Diagnostics Market. 20143. Allied Analytics. Global Oncology Drugs Market. 2015

For

per

sona

l use

onl

y

PipelineBalanced risk profile

■ Developing a pipeline of cancer diagnostic & therapeutic products based on its proprietary BARD1 technology

■ Lead product is BARD1 Lung Cancer Test for early detection of lung cancer

■ Research-stage pipeline targeting unmet needs in multiple cancers

PRODUCT INDICATION PLATFORM USE RESEARCHANAYTICAL VALIDATION

CLINICAL VALIDATION

MARKETABLE/ APPROVAL

BARD1 Lung Cancer Test

Lung CancerELISA1

(Blood)Screening & Diagnosis

2H17

BARD1 Ovarian Cancer Test

Ovarian CancerELISA (Blood)

Detection & Monitoring

BARD1 RNA Test

CancerRT-PCR (Blood)

Diagnosis & Monitoring

PRODUCT INDICATION RESEARCHPRE-CLINICAL

PHASE I PHASE II PHASE III APPROVAL

BARD1 Vaccine Cancer

DIA

GN

OS

TIC

ST

HE

RA

PE

UT

ICS

1ELISA = Enzyme Linked ImmunoSorbent Assay2RT-PCR = Reverse Transcriptase Polymerase Chain Reaction

For

per

sona

l use

onl

y

Lung CancerFacts■ Lung Cancer is the leading cause of cancer death

worldwide1

□ Incidence: 1.82m new cases pa□ Mortality: 1.59m deaths pa

■ Cancer types□ NSCLC (Non-Small Cell Lung Cancer): 85% cases□ SCLC (Small Cell Lung Cancer): 15% cases

■ Risk factors□ Smoking: 90% cases□ Other: age (>65y), second-hand smoke, radon exposure,

occupational exposure, cancer history, family history, lung disease

■ 5-year survival is linked to stage at detection2

□ Average 5-year survival 17.4% in US & 5.8% worldwide1

□ Late-detection is deadly: majority of patients diagnosed at late-stage with <1% survival

□ Early-detection saves lives: potentially >50% survival rate if diagnosed early

■ Early diagnosis is linked to improved prognosis & reduced mortality2,3

■ Global lung cancer diagnostics market US$26.0B in 2013 & US$42.2B by 2020, with 7.1% CAGR4

1%

14%

30%

49%

0% 20% 40% 60% 80% 100%

Stage 4

Stage 3

Stage 2

Stage 1

Survival

5-Year Survival Rate by Stage at Detection

It takes 10-20 years for lung cancer symptoms to appear and only 3-4 years for cancer to progress from Stage 1 to 4

Early detection saves lives!

1. GLOBOCAN 20122. ACS 20163. NCI 20144. TMR. Cancer Diagnostics Market. 2014

For

per

sona

l use

onl

y

Lung CancerUnmet need for early detection■ Current diagnostic options are limited

□ Chest X-ray: standard diagnostic tool in symptomatic patients, but not specific for LC

□ CT scan: ‘gold standard’ screening & diagnostic tool, but routine use limited by high false positives, additional diagnostic confirmation, radiation exposure & cost

□ Biopsy: ‘definitive diagnostic’ to determine cancer type & stage, but invasive & expensive

□ No simple blood test currently available

■ Treatment advances in surgery, radiotherapy & chemotherapy have not improved Overall Survival

■ However, early diagnosis has improved 5-year survival□ Low dose CT screening has shown a reduction in RR of mortality by 20% over chest X-ray1

□ Clinical guidelines recommend annual screening for lung cancer with LDCT2

■ Cancer screening is critical to enable early detection, improve prognosis & help inform treatment options

1. NCI 20142. NCCN, Guidelines 20163. TMR. Cancer Diagnostics Market. 2014LC = Lung CancerLDCT = Low Dose Computed TomographyRR = Relative Risk

Unmet need for a non-invasive, simple, accurate &

affordable screening test for early detection of lung cancer

NCCN Guidelines recommend “annual screening for lung cancer with low-dose computed tomography (LDCT) in high-risk asymptomatic adults aged 55-74 years with a greater than 30 pack-year smoking history that either continue to smoke or have quit within the past 15 years”

For

per

sona

l use

onl

y

BARD1 Lung Cancer TestSimple, accurate & affordable non-invasive blood test

■ BARD1 Test is a non-invasive blood test in development for early detection of lung cancer□ ELISA-assay detecting BARD1 autoantibodies in blood serum□ BARD1 antibodies detectable from early-stage tumours (improves accuracy for early-stage lung cancer)□ Specific BARD1 epitopes are used to capture anti-BARD1 antibodies specific for lung cancer□ Results are measured by electrochemiluminescence (ECL) in a dynamic-range system□ Meso Scale Diagnostics (MSD) engaged to optimise BARD1 Test on proven instrument platform to enable fast,

accurate & reliable testing at low cost

■ Intended use□ Screening test for early detection of lung cancer in high-risk asymptomatic individuals□ Diagnostic test for detection of lung cancer in symptomatic patients, or as a diagnostic aid to confirm CT scan

■ Parallel development of BARD1 Test for marketing or approval in Europe first then USA may speed development, reduce cost & lower regulatory hurdles

■ BARD1 Test offers potential advantages over other methods

Take blood sample (<1mL)

Doctor receives result to inform patient &

follow-up

Lab results in 3-5 days

Order blood test

Potential new first-line screening and diagnostic test for lung cancer

Convenient Simple blood collection, standard lab methods & fast results

Safe Non-invasive blood test can be repeated regularly & complements other diagnostic methods

Accurate Expected high sensitivity >90% and false positives <10%

Affordable Estimated $200 per test

For

per

sona

l use

onl

y

Proof of Concept Study Results

■ STUDY DESIGN: Controlled POC study in ~200 samples of lung cancer & healthy controls to determine the utility of circulating BARD1 antibodies as biomarkers for early detection of lung cancer

■ RESULTS: BARD1 diagnostic models accurately discriminated lung cancer from healthy controls1:□ Training sets: Average AUC=0.96, Sensitivity >95%,

False Positives <5% □ Validation set: Sensitivity >90%, False Positives <10%

■ CONCLUSION: High AUCs demonstrate POC that selected models accurately detect lung cancer with high specificity and sensitivity

1. BARD1. Results on file. 20162. Hiroaki Nomori et al. 2004AUC = Area Under CurveROC = Receiver Operating Characteristic

BARD1 Test more accurate than current gold standard LDCT

Typical ROC curve for CT Scan2

ROC curve for BARD1 Test

For

per

sona

l use

onl

y

Analytical ValidationCommenced

■ CONFIRMATION STUDY: Internal study to further develop & optimise prototype BARD1 Lung Cancer Test in over 450 samples of lung cancer and healthy controls for sensitivity & specificity of lung cancer in multiple cohorts comprising lung cancers of different types and stages, age, gender & ethnicity

■ ANALYTICAL VALIDATION STUDY: External study to transfer, optimise & validate the BARD1 Lung Cancer Test on proven instrument platform for reproducibility, repeatability, stability, precision, interference and limits if detection

■ RESULTS: expected 1Q17

For

per

sona

l use

onl

y

Clinical ValidationPlanned

■ PROSPECTIVE CLINICAL STUDY: □ Design: Prospective, multicentre clinical study of ~1000 high-risk asymptomatic

adults aged 55-74 years with a 30-pack year smoking history to demonstrate the safety and performance (sensitivity & specificity) of the BARD1 Lung Cancer Test compared to LDCT Scan for early detection of lung cancer

□ Objective: Verify that the BARD1 Lung Cancer Test achieves a lung cancer detection rate of greater than 90% and a false positive rate of less than 10%

□ Commencement: Expected 2H17

■ POST-MARKETING TRIALS: □ Additional studies may be required to demonstrate the clinical utility (reduced

mortality & improved quality of life) and health economic benefits of annual screening with the BARD1 Test compared to LDCT Scan over multiple years

Enable marketing or approval of laboratory tests under CE Mark in EU, ARTG Listing in

AU, and CLIA-certified LDT test followed by FDA-cleared IVD in US

For

per

sona

l use

onl

y

Ongoing BARD1 Research

■ Advance diagnostic pipeline for multiple cancers□ Accelerate development of new Diagnostic Tests for Ovarian and other

cancers

□ Initiate research to develop Liquid Biopsy products for diagnosis and treatment monitoring of cancer from blood and/or tissue samples

□ Partner to co-develop Companion Diagnostics for patient selection and monitoring of specific cancer treatments

■ Progress therapeutic pipeline for BARD1 positive cancers□ Collaborate to research and evaluate development of targeted

therapies for prevention or treatment of cancer

For

per

sona

l use

onl

y

Intellectual Property Portfolio

■ Strong IP portfolio with 5 patent families covering various BARD1 peptide sequences, methods of diagnosis & treatment, and use in multiple cancers

Patent Family Title StatusGranted Pending

Expiry

PCT/FR01/02731 Truncated BARD1 proteins and its diagnostic and therapeutic uses

US, JP 2023

PCT/IB2011/053635 BARD1 isoforms in lung and colorectal cancer and use thereof

US, EP, CA, JP, IL, CN, AU, BR, SG

2031

PCT/IB2011/054194 Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof

US, EP 2032

PCT/EP2014/073834 Lung Cancer Diagnosis US, EP, CA, JP,IL,CN, AU, SG, KR

2034

EP14002398.7 Novel non-coding RNA, cancer target and compounds for cancer treatment

US 2035

For

per

sona

l use

onl

y

Future MilestonesMultiple value-adding milestones & newsflowEvents Date (CY)

Commencement of Analytical Validation studies of BARD1 Lung Cancer Test for Lung Cancer 3Q16

Appointment of CEO 4Q16

Publish POC Study results in international peer-reviewed journal 1Q17

Expand R&D team 1Q17

Results of Analytical Validation studies of additional 450 samples 1Q17

Appoint Advisory Board 1H17

Commence Clinical Validation study of BARD1 Lung Cancer Test for early detection of Lung Cancer 2H17

Preliminary results of Clinical Validation study of BARD1 Lung Cancer Test 2018

CE Mark for marketing of BARD1 Lung Cancer Test in Europe 2019*

ARTG Listing for marketing of BARD1 Lung Cancer Test in Australia 2019*

Marketing of CLIA-certified LDT in USA 2019*

*Regulatory advice being sought on optimal regulatory strategy to firm up timelines

For

per

sona

l use

onl

y

Investment Highlights

Potential cancer diagnostics targeting unmet needs in US$101B global marketCommercially Compelling

Multiple publications validating BARD1 as a potential diagnostic marker & therapeutic target in multiple cancers

Proven Science

BARD1 biomarkers demonstrated as highly sensitive and specific for detection of Lung CancerPOC Completed

BARD1 Lung Cancer Test undergoing validation studies to develop, optimize & clinically validate the test for early detection of lung cancer

Commenced Validation

Non-invasive blood tests for early detection of cancer that are simple, accurate & affordableDiagnostic Advantages

Additional high-value diagnostic & therapeutic applications being evaluated for developmentFuture Pipeline

Broad patents covering technology, products and uses extending to 2035Solid IP

Scientific, clinical research & commercialisation expertise committed to delivering cancer detection & prevention solutions to improve patients’ lives

Experienced Leadership

Multiple milestone announcements & valuation inflection points over next 12-24 monthsStrong Newsflow

For

per

sona

l use

onl

y

Contact detailsBARD1 Life Sciences Ltd

Ground, Tempo Building, 431 Roberts Rd

Subiaco WA 6008 Australia

P +61 8 9381 9550 | E info@bard1.com | W www.bard1.com

Peter Gunzburg

Executive Chairman

E peter@bard1.com

M +61 412 927 773

Dr Leearne Hinch

CEO

E leearne@bard1.com

For

per

sona

l use

onl

y

AcronymsAUC Area Under the Curve is an index of the accuracy of a diagnostic test to discriminate between diseased and healthy states

Biomarker Serum marker of disease state

CE Mark Communaute/Conformite European mark certifying that a product has met EU consumer safety, health or environmental requirements

CLIA Clinical Laboratory Improvement Amendment of 1988

CMC Chemistry, Manufacturing & Controls

CRO Contract Research Organisation

ctDNA Circulating tumour DNA in a Liquid Biopsy test

ELISA Enzyme-Linked Immunosorbent Assay

FDA Food and Drug Administration is the US regulatory authority for medical drugs and devices

Incidence Number of new cases of a disease in a population during a given time period

IVD In Vitro Diagnostic

IP Intellectual Property

LDCT Low Dose Computed Tomography

LDT Laboratory Developed Test

PCT Patent Cooperation Treaty

Prevalence Number of total cases of a disease in a population over a given time period

QOL Quality of Life

ROC Receiver Operating Characteristics

RR Relative Risk

RT-PCR Reverse Transcriptase Polymerase Chain Reaction

TGA Therapeutic Goods Administration is the Australian agency for evaluation of medical goods

For

per

sona

l use

onl

y